• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Neurelis closes Series B for intranasal diazepam spray

January 5, 2017 By Sarah Faulkner

Neurelis closes Series B for intranasal diazepam sprayNeurelis, Inc. said today that it closed a Series B financing round, led by HBM Healthcare Investments. Other investors included LYZZ Capital, which previously led a Series A funding round for the company. Neurelis will use the funds to complete clinical trials for its intranasal diazepam spray and prepare a new drug application to submit to the FDA.

The round, which closed at an undisclosed amount, comes just 1 day after the company said that the FDA granted fast track designation for its diazepam spray, NRL-1. The intranasal formulation is being developed for pediatric and adult epilepsy patients with acute repetitive or cluster seizures.

The company said it expects to submit the new drug application to the FDA in 2018.

“We are very excited to have completed the company’s Series B financing round,” president & CEO Craig Chambliss said in prepared remarks. “We are pleased to bring an outstanding investor in HBM Healthcare to the Neurelis team and greatly appreciate the continued confidence that LYZZ Capital has shown with their full participation in this financing.  We can now complete the clinical development work for NRL-1, assemble our NDA submission, and prepare for the commercialization of this important orphan drug product for the epilepsy community.”

Neurelis won orphan drug designation for NRL-1 in November 2015. The nasal spray delivers a therapeutic dose of diazepam, in the hopes of quickly providing treatment when seizures occur.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Funding Roundup, Neurological Tagged With: Neurelis Inc.

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS